Monograph Title | Section | Source Publication Sort descending | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
HYDROXYPROPYL CELLULOSE | ASSAY | Second Supplement to USP37–NF32 | 7080 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Internal standard solution: Change Methycyclohexane to: Methylcyclohexane |
POLYSORBATE 80 | SPECIFIC TESTS/Fats and Fixed Oils, Acid Value <401> | Second Supplement to USP37–NF32 | 7089 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 1 of Analysis: Change with 0.1 N potassium hydroxide or 0.1 N sodium hydroxide to: with 0.1 N potassium hydroxide VS or 0.1 N sodium hydroxide VS |
DACARBAZINE FOR INJECTION | IMPURITIES/Limit of 2-Azahypoxanthine | Second Supplement to USP37–NF32 | Online | 26-Sep-2014 | 1-Oct-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 2 of Analysis: Change 2-azahypoxanthine monohydrate to: 2-azahypoxanthine |
MEBENDAZOLE | ASSAY/Procedure | Second Supplement to USP37–NF32 | 7199 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 3 of Analysis: Change Calculate the percentage of each impurity in the portion of Oral Suspension taken: to: Calculate the percentage of mebendazole (C16H13N3O3) in the portion of Mebendazole taken: |
SODIUM PICOSULFATE | CHEMICAL INFORMATION | Second Supplement to USP37–NF32 | 7253 | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Line 5: Change Disodium 4,4′-(pyridin-2-ylmethanediyl)dibenzenesulfonate to: Disodium 4,4′-(pyridin-2-ylmethanediyl)dibenzenesulfate |
RISPERIDONE ORAL SOLUTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP37–NF32 | Online | 25-Jul-2014 | 1-Aug-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Line 2 of USP Risperidone Related Compounds Mixture RS: Change Contains a mixture of the following four compounds: 98.9% of Risperidone. 0.5% of Risperidone cis-N-oxide: cis-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4… Read More |
TIZANIDINE TABLETS | ASSAY/Procedure/System suitability | Second Supplement to USP37–NF32 | Online | 25-Jul-2014 | 1-Aug-2014 | USP39–NF34 | First Supplement to USP38–NF33 | Change Sample: Standard solution to: Samples: System suitability solution and Standard solution AND Change Resolution: NLT 4.0 between tizanidine and tizanidine related compound C; NLT 4.0 between tizanidine and tizanidine related compound… Read More |
FENTANYL | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP37–NF32 | Online | 21-Nov-2014 | 1-Dec-2014 | USP39–NF34 | Second Supplement to USP38–NF33 | Delete USP Fentanyl Related Compound C RS AND Delete USP Fentanyl Related Compound F RS |
NIFEDIPINE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2 | Second Supplement to USP37–NF32 | Online | 21-Nov-2014 | 1-Dec-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Solution A: Change sodium phosphate to: dibasic sodium phosphate |
CHLORPHENIRAMINE MALEATE | SPECIFIC TESTS/Optical Rotation, Specific Rotation <781> | Second Supplement to USP38–NF33 | Online | 25-Sep-2015 | 1-Oct-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 1: Delete Specific Rotation |
<1132> RESIDUAL HOST CELL PROTEIN MEASUREMENT IN BIOPHARMACEUTICALS | 4. HCP IMMUNOASSAY METHOD VALIDATION/4.3 Sample Linearity/Table 4 | Second Supplement to USP38–NF33 | 7647 | 25-Mar-2016 | 1-Apr-2016 | USP40–NF35 | USP40–NF35 | Product column: Change 10.00 (neat), 5.00, 2.50, 1.25, 0.63, 0.31, 0.16 to: 10.00 (neat), 5.00, 2.50, 1.25, 0.625, 0.3125, 0.15625 AND Sample 1/HCP ratio column: Change 4.9, 5.7, 4.8, 5.9, 5.0, 5.1, <6 to: 4.90, 5.70, 4.80, 5.92, 4.96, 5.12, <6 AND… Read More |
DESCRIPTION AND SOLUBILITY | SUNFLOWER OIL | Second Supplement to USP38–NF33 | 7761 | 20-Nov-2015 | 1-Dec-2015 | USP40–NF35 | Second Supplement to USP39–NF34 | Line 5: Change NF category: Coating agent; emollient; solvent; tablet and/or capsule diluent; vehicle (oleaginous). to: NF category: Coating agent; emollient; solvent; diluent; vehicle (oleaginous). |
MILK THISTLE | COMPOSITION/Content of Silymarin | Second Supplement to USP38–NF33 | 7878 | 20-Nov-2015 | 1-Dec-2015 | USP40–NF35 | Second Supplement to USP39–NF34 | Line 3 of Sample stock solution: Change Transfer the thimble to a continuous-extraction apparatus fitted with a 250-mL round-bottom flask containing 150 mL of hexane, and heat the flask on a heating mantle for 4 h. After the extraction, detach the round-bottom flask from the extraction… Read More |
POWDERED MILK THISTLE | COMPOSITION/Content of Silymarin | Second Supplement to USP38–NF33 | 7880 | 20-Nov-2015 | 1-Dec-2015 | USP40–NF35 | Second Supplement to USP39–NF34 | Line 3 of Sample stock solution: Change Transfer the thimble to a continuous-extraction apparatus fitted with a 250-mL round-bottom flask containing 150 mL of hexane, and heat the flask on a heating mantle for 4 h. After the extraction, detach the round-bottom flask from the extraction… Read More |
CORTICOTROPIN INJECTION | ASSAY/Procedure | Second Supplement to USP38–NF33 | 8059 | 20-Nov-2015 | 1-Dec-2015 | USP40–NF35 | Second Supplement to USP39–NF34 | Line 7 of Replication: Change (see <111>, Confidence Intervals for Individual Assays). to: (see <111>, The Confidence Interval and Limits of Potency). |
CORTICOTROPIN FOR INJECTION | ASSAY/Procedure | Second Supplement to USP38–NF33 | 8061 | 20-Nov-2015 | 1-Dec-2015 | USP40–NF35 | Second Supplement to USP39–NF34 | Line 7 of Replication: Change (see <111>, Confidence Intervals for Individual Assays). to: (see <111>, The Confidence Interval and Limits of Potency). |
REPOSITORY CORTICOTROPIN INJECTION | ASSAY/Procedure | Second Supplement to USP38–NF33 | 8063 | 20-Nov-2015 | 1-Dec-2015 | USP40–NF35 | Second Supplement to USP39–NF34 | Line 7 of Replication: Change (see <111>, Confidence Intervals for Individual Assays). to: (see <111>, The Confidence Interval and Limits of Potency). |
LOPINAVIR AND RITONAVIR ORAL SOLUTION | IMPURITIES/Organic Impurities | Second Supplement to USP38–NF33 | 8139 | 20-Nov-2015 | 1-Dec-2015 | USP40–NF35 | Second Supplement to USP39–NF34 | Row 17 of Column 3 of Table 2: Change 0.2 to: 0.2p AND Add footnote pDisregard any peak less than 0.01%. |
<232> ELEMENTAL IMPURITIES--LIMITS | DRUG SUBSTANCE AND EXCIPIENTS/Table 2 | Second Supplement to USP38–NF33 | 7594 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 1 of Row 1 of Column 2: Change (g/g) to: (µg/g) AND Line 1 of Row 1 of Column 3: Change (g/g) to: (µg/g) AND Line 1 of Row 1 of Column 4: Change (g/g) to: (µg/g) |
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLETS | IMPURITIES/Organic Impurities | Second Supplement to USP38–NF33 | 8158 | 20-Nov-2015 | 1-Dec-2015 | USP40–NF35 | Second Supplement to USP39–NF34 | Row 6 of Column 2 of Table 5: Change 0.62 to: 0.82 |
MANNITOL INJECTION | Specific rotation <781> | Second Supplement to USP38–NF33 | Online | 20-Nov-2015 | 1-Dec-2015 | USP40–NF35 | Second Supplement to USP39–NF34 | Line 1: Change Transfer an accurately measured volume of Injection, equivalent to about 1 g of mannitol as determined by the Assay, to a 100-mL volumetric flask:it meets the requirements of the test for Specific rotation under Mannitol. to: +137° to +145°.Transfer… Read More |
SODIUM CHLORIDE | IMPURITIES/Limit of Potassium/Instrumental conditions | Second Supplement to USP39–NF34 | 8821 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Mode: Change Atomic absorption spectrophotometry to: Atomic emission spectroscopy |
OMEGA-3-ACID ETHYL ESTERS CAPSULES | SPECIFIC TESTS/Concentration of Omega-3-Acid Ethyl Esters | Second Supplement to USP39–NF34 | 8755 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 21: Change CU = nominal concentration of the total omega-3-acid ethyl esters in the Sample solution (g/mL) to: CU = Capsule fill content of the Sample solution (g/mL) |
TACROLIMUS CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 5 | Second Supplement to USP39–NF34 | 8834 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1 of Medium: Change 0.5 g/L to: 0.05 g/L |
POVIDONE | IMPURITIES/Formic Acid | Second Supplement to USP39–NF34 | 8778 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 3 of Sample solution: Change column of about 80 mm to: column of about 8 mm |
ROPINIROLE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 1 | Second Supplement to USP39–NF34 | 8814 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of Buffer 1: Adjust with Solution A to a pH of 4.0. to: Adjust with Solution A to a pH of 4.0. Dilute with water to 1 L. |
THEOPHYLLINE | ADDITIONAL REQUIREMENTS/USP Reference Standards RS <11> | Second Supplement to USP39–NF34 | 8844 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 3 of USP Theophylline Related Compound D RS: Change N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide. C6H10N4O 154.17 to: N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide hydrochloride monohydrate. C6… Read More |
THEOPHYLLINE ORAL SOLUTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF34 | 8846 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 3 of USP Theophylline Related Compound D RS: Change N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide. C6H10N4O 154.17 to: N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide hydrochloride monohydrate. C6… Read More |
DESLORATADINE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF34 | 8607 | 30-Sep-2016 | 1-Oct-2016 | USP41–NF36 | First Supplement to USP40–NF35 | Line 2 of USP Desloratadine Related Compound B RS: Change 8-Chloro-11-(1,2,3,6-tetrahydropyridin-4-yl)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine. C19H19ClN2 310.82 to: 8-Chloro-11-(1,2,3,6-tetrahydropyridin-4-yl)-6,11-dihydro-5… Read More |
OMEGA-3-ACID ETHYL ESTERS CAPSULES | ASSAY/Content of EPAee, DHAee, and Total Omega-3-Acid Ethyl Esters/Analysis | Second Supplement to USP39–NF34 | 8755 | 29-Jul-2016 | 1-Aug-2016 | USP41–NF36 | First Supplement to USP40–NF35 | Line 16 of the third equation: Change L = label claim of total omega-3-acids ethyl esters (g/Capsule) to: L = label claim of total omega-3-acids ethyl esters (mg/Capsule) |
NAPROXEN SODIUM TABLETS | IMPURITIES/Organic Impurities | Second Supplement to USP39–NF34 | Online | 29-Jul-2016 | 1-Aug-2016 | USP41–NF36 | First Supplement to USP40–NF35 | Line 6 of Analysis: Change Result = (rU/rS) × (CU/CS) × 100 to: Result = (rU/rS) × (CS/CU… Read More |
REAGENTS, INDICATORS AND SOLUTIONS | Solutions/Volumetric Solutions | Second Supplement to USP39–NF34 | 8458 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 3 of 0.07 N Ferrous Ammonium Sulfate VS: Change In a 100-mL volumetric flask, to: In a 1000-mL volumetric flask, |
MAGNESIUM ALUMINUM SILICATE | SPECIFIC TESTS/Viscosity/Acceptance criteria | Second Supplement to USP39–NF34 | 8558 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 1 of Type IA: Change 225–600 to: 225–600mPa · s AND Line 1 of Type IB: Change 150–450 to: 150–450 mPa · s AND Line 1 of Type IC: Change 800–2200 to: 800–2200 mPa · s AND Line 1 of Type IIA: Change 100–300 to: … Read More |
ROPINIROLE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities/Analysis | Second Supplement to USP39–NF34 | 8814 | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 8 of the variable definition list of the first equation: Change CU = nominal concentration of ropinirole related compound B free base in the Sample solution (µg/mL) to: CU = nominal concentration of ropinirole in the … Read More |
IMIPRAMINE PAMOATE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 1 | Second Supplement to USP39–NF34 | 8681 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 6 of Analysis: Change Resulti = (ri/rs) × Cs × [M × (Mr1/Mr2)] × V x (1/L) × 100 to: Resulti… Read More |
PROMETHAZINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF34 | 8784 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Promethazine Related Compound B RS: Change Isopromethazine; N,N-Dimethyl-2-(10H-phenothiazin-10-yl)propan-1-amine. C17H20N2S 282.42 to: Isopromethazine hydrochloride; N,N-Dimethyl-2-(10H-… Read More |
CIPROFLOXACIN | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF34 | 8597 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Ciprofloxacin Ethylenediamine Analog RS: Change 7-(2-Aminoethylamino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid. C15H16FN3O3 305.30 to: 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)… Read More |
PROMETHAZINE HYDROCHLORIDE INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF34 | 8785 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Promethazine Related Compound B RS: Change Isopromethazine; N,N-Dimethyl-2-(10H-phenothiazin-10-yl)propan-1-amine. C17H20N2S 284.42 to: Isopromethazine hydrochloride; N,N-Dimethyl-2-(10H-… Read More |
PROMETHAZINE HYDROCHLORIDE ORAL SOLUTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF34 | 8787 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Promethazine Related Compound B RS: Change Isopromethazine; N,N-Dimethyl-2-(10H-phenothiazin-10-yl)propan-1-amine. C17H20N2S 282.42 to: Isopromethazine hydrochloride; N,N-Dimethyl-2-(10H-… Read More |
DEXTROSE | IDENTIFICATION/C. Water Determination <921> | Second Supplement to USP39–NF34 | 8612 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 1: Change Water Determination <921> to: Water Determination <921>, Method I |
PROMETHAZINE HYDROCHLORIDE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF34 | 8788 | 27-Jan-2017 | 1-Feb-2017 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Promethazine Related Compound B RS: Change Isopromethazine; N,N-Dimethyl-2-(10H-phenothiazin-10-yl)propan-1-amine. C17H20N2S 284.42 to: Isopromethazine hydrochloride; N,N-Dimethyl-2-(10H-… Read More |
OMEGA-3-ACID ETHYL ESTERS CAPSULES | ASSAY/Content of EPAee, DHAee, and Total Omega-3-Acid Ethyl Esters | Second Supplement to USP39–NF34 | 8755 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 21 of Analysis: Change CU = nominal concentration of the total omega-3-acid ethyl esters in the Sample solution (g/mL) to: CU = Capsule fill content of the Sample solution (g/mL) |
CIPROFLOXACIN HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP39–NF35 | 8600 | 18-Nov-2016 | 1-Dec-2016 | USP41–NF36 | Second Supplement to USP40–NF35 | Line 2 of USP Ciprofloxacin Ethylenediamine Analog RS: Change 7-(2-Aminoethylamino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid. C15H16FN3O3 305.30 to: 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)… Read More |
SODIUM LAURYL SULFATE | IDENTIFICATION | Second Supplement to USP40–NF35 | 8946 | 17-Nov-2017 | 1-Dec-2017 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 1 of A.: Change Infrared Absorption <197K> or <197A> to: ⧫A. Infrared Absorption <197K> or <197A>⧫ |
<191> IDENTIFICATION TESTS—GENERAL | CHEMICAL IDENTIFICATION TESTS/Thiosulfate | Second Supplement to USP40–NF35 | Online | 17-Nov-2017 | 1-Dec-2017 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 1 of A.: Change yellow; with the addition of sulfur dioxide, filter paper moistened with mercurous nitrate TS blackens. to: yellow, and evolve sulfur dioxide, which blackens filter paper moistened with mercurous nitrate TS. |
CANDESARTAN CILEXETIL TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Second Supplement to USP40–NF35 | 8730 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 2 of USP Candesartan Cilexetil Related Compound D RS: Change 1-{[(Cyclohexyloxycarbonyloxy)carbonyl]oxy}ethyl 3-{[2’-(2-ethyl-2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-2-oxo-2,3-dihydro-1H-benzimidazole-4-carboxylate. to: 1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl 3-({2’-(2-… Read More |
FLUVOXAMINE MALEATE | CHEMICAL INFORMATION | Second Supplement to USP40–NF35 | 8797 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 4:Change 5-Methoxy-4’-(trifluoromethyl)valerophenone (E)-O-(2-aminoethyl)oxime, maleate (1:1) to: (E)-5-Methoxy-4’-(trifluoromethyl)valerophenone O-(2-aminoethyl)oxime, maleate (1:1) |
FLUVOXAMINE MALEATE | IMPURITIES/Organic Impurities/Table 1 | Second Supplement to USP40–NF35 | 8797 | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Footnote b:Change 5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone (E)-O-[2-[(2-succinyl)amino]ethyl]oxime. to: (E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone O-[2-[(2-succinyl)amino]ethyl]oxime. AND Footnotes c– g: Delete the space before… Read More |
EFAVIRENZ | SPECIFIC TESTS/Enantiomeric Purity | Second Supplement to USP40–NF35 | Online | 29-Sep-2017 | 1-Oct-2017 | USP42–NF37 | First Supplement to USP41–NF36 | Line 1 of Mobile phase: Change Hexane and ethanol (97:3) to: Hexane and absolute alcohol (97:3) |
TIMOLOL MALEATE | MULTIPLE SECTIONS | Second Supplement to USP40–NF35 | Online | 28-Jul-2017 | 1-Aug-2017 | USP41–NF36 | USP41–NF36 | The version of the Timolol Maleate monograph which appeared in the Second Supplement to USP 40–NF 35 did not include the revisions approved in the version appearing in the First Supplement to USP 40–NF 35. The version appearing in the First Supplement should be used. The file… Read More
|